ResMed Inc. (RSMDF) will report fiscal 2026 earnings on April 21, marking another critical test for the healthcare medical devices giant. With a $36.26 billion market cap and strong operational momentum, investors are watching closely. The company has consistently beaten estimates over recent quarters, with EPS outperformance and solid revenue growth. ResMed’s focus on sleep and respiratory care devices, plus cloud-based software solutions, positions it well in an aging population. Meyka AI rates RSMDF with a grade of B+, reflecting solid fundamentals and growth prospects. This earnings preview examines what to expect and why this report matters for your portfolio.
What Analysts Expect From ResMed Earnings
ResMed’s earnings preview comes as the company faces a critical quarter. Analyst expectations remain cautious without specific consensus estimates available for this report. However, historical performance provides strong guidance on what to watch.
Recent Beat Pattern
ResMed has demonstrated consistent outperformance. In the most recent quarter (January 29, 2026), the company delivered $0.281 EPS against a $0.2748 estimate, beating by 2.3%. Revenue came in at $1.42 billion versus $1.40 billion expected, a 1.5% beat. This pattern of consistent outperformance suggests management execution remains strong and operational efficiency is improving.
Historical Consistency
Looking back four quarters, ResMed has beaten EPS estimates in three of the last four reports. The October 2025 quarter showed $0.255 EPS versus $0.252 expected. Revenue growth has remained steady, averaging $1.35 billion across recent quarters. This consistency indicates stable demand for respiratory and sleep care solutions.
Revenue and EPS Trends: Building Momentum
ResMed’s financial trajectory shows improving fundamentals across multiple dimensions. The company’s earnings history reveals a business gaining traction in key markets.
Revenue Growth Acceleration
Revenue has grown from $1.29 billion (July 2025) to $1.42 billion (January 2026), representing 10.1% growth over six months. This acceleration reflects strong demand for cloud-based software solutions and medical devices. The company’s 9.8% year-over-year revenue growth demonstrates resilience despite healthcare sector headwinds. Gross margins remain healthy at 61%, providing cushion for investments in R&D and sales expansion.
EPS Expansion Story
Earnings per share have expanded from $0.2475 (April 2025) to $0.281 (January 2026), a 13.5% increase. This outpaces revenue growth, indicating operational leverage and improved profitability. The company’s 27.5% net profit margin ranks among healthcare’s best. With 1.46 billion shares outstanding, ResMed maintains disciplined capital allocation while investing in growth.
Key Metrics and What to Watch
Beyond headline numbers, several metrics will determine if ResMed sustains its growth trajectory. Investors should focus on specific operational indicators.
Software Segment Performance
ResMed’s Software-as-a-Service business is critical. This segment includes cloud platforms like AirView, myAir, and MatrixCare. Watch for SaaS revenue growth rates and recurring revenue percentages. The company’s $36.85 revenue per share and strong $13.07 operating cash flow per share indicate robust cash generation. SaaS margins typically exceed 70%, so any acceleration here signals future profitability gains.
Device Segment Stability
The Sleep and Respiratory Care segment remains the revenue anchor. Monitor unit volumes, pricing trends, and geographic mix. ResMed’s $12.21 free cash flow per share demonstrates the device business still generates substantial cash. Watch for commentary on supply chain normalization and international expansion, particularly in emerging markets where respiratory disease prevalence is rising.
Balance Sheet Strength
ResMed maintains a fortress balance sheet with $9.74 cash per share and a 0.16 debt-to-equity ratio. The company’s 3.06 current ratio provides flexibility for acquisitions or shareholder returns. Dividend payments of $2.33 per share remain sustainable given $13.07 operating cash flow per share. Watch for any changes to capital allocation strategy or M&A activity.
Meyka AI Grade and Investment Implications
Understanding ResMed’s valuation and quality metrics helps frame earnings expectations. Meyka AI’s comprehensive analysis provides important context.
B+ Grade Breakdown
Meyka AI rates RSMDF with a grade of B+, reflecting solid fundamentals and sector positioning. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 76.2 out of 100 indicates above-average quality but not exceptional. ResMed ranks well on profitability metrics (ROE of 24.8%, ROA of 17.5%) but faces valuation headwinds with a 22.4 P/E ratio and 6.15 price-to-sales multiple.
Valuation Context
At $24.89 per share, ResMed trades at a 5.27 price-to-book ratio, suggesting investors pay premium prices for quality. The 18.5 price-to-free-cash-flow ratio is reasonable for a healthcare compounder. Meyka’s forecast model projects $28.68 yearly and $36.02 in three years, implying 15% annualized returns. This assumes consistent execution and market share gains in cloud-based healthcare solutions.
Final Thoughts
ResMed’s April 21 earnings report will test whether the company can sustain its beat streak and revenue acceleration. With consistent outperformance over recent quarters, strong cash generation, and a fortress balance sheet, the setup appears favorable. Investors should focus on SaaS segment growth, device volume trends, and management commentary on international expansion. The B+ Meyka grade reflects solid quality, though valuation at 22.4x earnings leaves limited margin for disappointment. Watch for any guidance changes or M&A announcements that could reshape the growth narrative. These grades are not guaranteed and we are not financial advisors.
FAQs
What is the ResMed earnings date and time?
ResMed reports fiscal 2026 earnings on April 21, 2026, after market close. The company typically hosts a conference call with analysts at 4:30 PM ET. Check ResMed’s investor relations website for exact timing and dial-in details.
Has ResMed beaten earnings estimates recently?
Yes. ResMed beat EPS estimates in three of the last four quarters. Most recently (January 2026), it delivered $0.281 EPS versus $0.2748 expected, a 2.3% beat. Revenue also beat by 1.5%, showing consistent operational execution and strong demand.
What should investors watch in this earnings report?
Monitor SaaS revenue growth rates, device segment unit volumes, and international expansion commentary. Watch for guidance changes, margin trends, and any M&A announcements. Also track free cash flow and dividend sustainability given the $2.33 annual payout.
What does ResMed’s B+ Meyka grade mean?
The B+ grade (76.2/100) indicates above-average quality with solid fundamentals. It reflects strong profitability (24.8% ROE), good cash generation, and sector positioning. However, the 22.4x P/E valuation suggests limited margin for disappointment in earnings.
Is ResMed a good investment before earnings?
ResMed shows strong fundamentals with consistent beats, 27.5% net margins, and $12.21 free cash flow per share. However, valuation at 22.4x earnings leaves little room for error. Consider waiting for earnings results to assess guidance before making investment decisions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)